Merck & Co (MRK)

Merck (MRK) offers a strong 3.43% dividend yield, backed by a history of increases, high profitability, and solid financial health for durable income.

This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program.

This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors.

As the calendar turns toward 2026, the exuberant "AI-everything" rally that defined much of 2024 and 2025 is facing a sobering reality check. With the Federal Reserve entering a delicate transition phase and inflation proving stickier than many had hoped, Wall Street is dusting off the playbook from the 2022

While one of the drugs reportedly slated for fast-track review is the cholesterol pill Enlicitide decanoate, the other is its cancer therapy Sacituzumab tirumotecan.

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.

Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to deliver.

New York, NY – December 16, 2025 – Pfizer Inc. (NYSE: PFE) today delivered a sobering financial outlook for 2026, projecting revenue and adjusted earnings per share (EPS) that fell short of Wall Street's expectations. The announcement immediately sent shockwaves through the market, with Pfizer's stock experiencing a notable decline as investors

Each company has a bullish case, but three stand out as great long-term buys.

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the S&P500 gap up and gap down stocks in today's session.

It's hard to beat dividend-paying stocks -- in part because they tend to increase their payouts regularly.

Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

They could grow into their valuation over the next few years.

As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more traditional value sectors and defensive equities. This ongoing recalibration reflects evolving macroeconomic conditions, a reassessment of risk appetite, and a growing

The semiconductor industry, the foundational bedrock of our digital world and the engine powering the explosive growth of artificial intelligence, is undergoing a profound transformation. Driven by escalating environmental concerns, stringent regulatory demands, and a heightened sense of corporate responsibility, chip manufacturers are increasingly prioritizing energy efficiency and sustainable practices in every facet of chip [...]

Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing market opportunities and must invest heavily to expand further, a risky proposition.

Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.

New York, NY – December 9, 2025 – The S&P 500 Healthcare sector found itself in a precarious position today, emerging as the biggest underperformer among its peers. While the broader S&P 500 index largely treaded water, the healthcare segment registered a notable decline of 0.5%, extending a three-day

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session.

The company is finding ways to overcome the headwinds it will encounter in the medium term.

Blockbuster drugs are a major driver of the growth of healthcare stocks.

With yields between 3.4% and 6.8%, you'll need to think carefully about the highest yields in the Dow before you buy them.

After a long hiatus, why are the bulls so willing to buy in now?